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The molecular mechanisms involved in the pathogenesis of 
chronic obstructive pulmonary disease (COPD) are poorly 
defined. Accumulating evidences indicate that chronic in-
flammatory responses and adaptive immunity play important 
roles in the development and progression of the disease.  
Recently, it has been shown that IL-17 producing CD4 T cells, 
named Th17 cells, which have been implicated in the patho-
genesis of several inflammatory and autoimmune diseases, 
are involved in airway inflammation and COPD. In addition, 
we and others suggest that autoimmunity may play a critical 
role in the pathogenesis of COPD. Here, we will review the 




COPD is a comprehensive disease including chronic bronchi-
tis and emphysema, and is characterized by the pathological 
limitation of airflow in the airway associated with chronic in-
flammation  and  alveolar  destruction  (1).  It  is  one  of  major 
causes of morbidity and mortality throughout the world and 
projected to become the third cause of death world-wide by 
2030 (2). Although tobacco smoke is a well-known cause of 
the  disease,  the  precise  mechanisms  of  chronic  progressive 
alveolar  destruction  are  not  well  defined.  Further,  not  all 
smokers  develop  the  clinical  overt  COPD  and  pathological 
process persists despite smoking cessation (3-5). Recently, it 
has  been  proposed  that  other  mechanisms  such  as  chronic 
inflammation,  cellular  senescence,  and  apoptosis  are  im-
plicated in the development and progression of the disease 
(6-9).  A  potential  role  for  adaptive  immune  responses  in 
COPD  has  been  suggested  in  recent  studies  that  show  ex-
pansion of lung T cells and B cells with oligoclonality in pa-
tients with COPD and/or murine emphysema model (10-12).   
In addition, it has recently been proposed that COPD could 
be associated with autoimmune responses (13).  In this re-
view, we will briefly summarize and discuss the roles of in-
flammatory responses including Th17 cell-mediated response 
and  autoimmunity  in  the  pathogenesis  of  COPD.
INFLAMMATION IN COPD
I n  p a t i e n t s  w i t h  C O P D ,  t h e r e  a r e  a c c u m u l a t i o n  o f  i n -
flammatory  mucous  exudates  in  the  airway  lumen  and  in-
creased numbers of inflammatory cells including neutrophils, 
macrophages, and  T  cells  in the lung parenchyma. Progre-
ssion of the disease is associated with an infiltration of innate 
and adaptive inflammatory immune cells that form lymphoid 
follicles (14). There have been a number of studies investigat-
ing the key inflammatory cells, cytokines, and chemokines in 
the  pathogenesis  of  COPD  (14-17).
    Inhaled cigarette smoke activates lung epithelial cells and 
alveolar  macrophages  to  release  several  chemotactic  factors 
which attract inflammatory cells to the lung. Neutrophils are 
accumulated  in  the  sputum,  bronchoalveolar  lavage  (BAL) 
and airway smooth muscle of patients with COPD, and this 
correlates  with  disease  severity  (15,16).  The  infiltration  of 
neutrophils is proportional to the production of chemokines Role of Th17 Cell and Autoimmunity in Chronic Obstructive Pulmonary Disease
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such  as  CXCL1  (GRO-α )  and  CXCL8  (also  known  as  IL-8), 
which  act  on  CXCR2  to  attract  neutrophils  and  monocytes.   
The levels of CXCL1 and CXCL8 are markedly increased in 
induced sputum of patients with COPD (17). Neutrophils can 
contribute to the pathogenesis of COPD through secretion of 
proteolytic  enzymes  such  as  neutrophil  elastase  (NE)  (18).   
NE has a potent catalytic activity against extracellular matrix 
including elastin that is one of major components of the lung.   
Further, NE can cause mucus hyper-secretion (19). In addi-
tion to neutrophils, macrophage is another chief candidate for 
causing lung pathology in COPD. There is evidence that al-
veolar macrophages play a critical role in the pathophysiol-
ogy of COPD through release of chemokines that attract neu-
trophils, monocytes and T cells, and secretion of proteases, 
particularly, matrix metalloproteinase-9 (MMP-9) and MMP-12 
(20). MMPs process a large array of extracellular and cell sur-
f a c e  p r o t e i n s ,  a n d  i t  h a s  b e e n  s u g g e s t e d  t h a t  d y s r e g u l a t i o n 
of MMPs contribute to the destruction of lung tissue in COPD 
(21). In those studies, BAL fluid or alveolar macrophages of 
subjects with COPD show a higher concentration and activity 
of MMP-9  compared  with  normal controls (22,23).  The im-
portance of MMP-12 in COPD is also supported by an animal 
model that mice lacking MMP-12 were completely protected 
from cigarette smoking induced emphysema (24).  In addi-
tion,  lung  tissues  from  COPD  patients  show  larger  number 
of  macrophages  expressing  MMP-12  than  those  of  control 
subjects  (25).
    Pro-inflammatory cytokines including tumor necrosis factor-
α (TNF-α ), interleukin-1β (IL-1β ), and IL-6 have roles in 
the pathogenesis of other inflammatory diseases such as rheu-
matoid arthritis and inflammatory bowel diseases. The clinical 
benefit  of  blockade  of  those  cytokines  in  chronic  inflam-
matory  diseases  leads  to  interest  in  whether  this  approach 
might also have effect on treatment of COPD. In murine mod-
el, over-expression of TNF-α  in lung tissue causes alveolar 
destruction, increases in lung volumes, and decreases in elas-
tic recoil, which are characteristics of COPD and emphysema 
(26).  The  level  of  TNF-α  i s in c re ase d  in  spu t um  o f CO P D 
patients  relative to  that  of  normal control  subjects,  and  the 
increase  is  more  prominent  during  acute  exacerbation  of 
COPD (16,27). However, clinical application of TNF blocking 
antibody in COPD patients is not promising, and there is a 
risk  of  respiratory  tract  infections  with  this  therapy,  raising 
needs of additional work to elucidate the functional role of 
TNF-α in  COPD  (28,29).  IL-1β and  IL-6  are  mediators  of 
inflammatory responses, and the concentration of these cyto-
kines  is  elevated  in  patients  with  COPD  (30,31).  IL-32  is  a 
newly  described  pro-inflammatory  cytokine  produced  by  T 
cells, natural killer cells, monocytes and epithelial cells, and 
its expression is increased in lung tissue of COPD patients. 
This study demonstrated that IL-32 expression was positively 
correlated with TNF-α  production and the degree of airflow 
limitation (32). However, the functional role of these pro-in-
f l a m m a t o r y  c y t o k i n e s  t h a t  a r e  i n c r e a s e d  i n  p a t i e n t s  w i t h  
COPD  has  not  yet  been  fully  elucidated.
TH17 CELL-MEDIATED IMMUNITY IN COPD
T  lymphocytes  are  one  of  the  key  components  of  in-
flammation in COPD. Th17 cells are recently described effec-
tor T cell subsets characterized by the production of IL-17A, 
IL-17F and IL-22, which have been implicated in the patho-
genesis  of  several  inflammatory  and  autoimmune  diseases 
(33,34). IL-17 is a pro-inflammatory cytokine that regulates re-
cruitment  of  inflammatory  cells  including  neutrophils  and 
lymphocytes into the inflamed tissues by secretion of chemo-
kines-CXCL8  and  CCL20  (35,36).  Additionally,  IL-17  has  an 
effect on most parenchymal cells including macrophages and 
dendritic  cells  (DCs)  that  express  IL-17  receptors,  and 
IL-17-mediated signaling induces target cells to produce vari-
ous  inflammatory  mediators  such  as  TNF-α  a n d  I L - 6 .    
Recently, it has been reported the role of Th17 response in 
lung physiology and pathology. IL-17 can induce airway epi-
thelial  cells  to  produce  mucus  and  MMP-9  (37).  Further, 
over-expression of IL-17 in murine lung epithelium causes ac-
cumulation  of  mononuclear  cells  and  mucus  production.   
This study has demonstrated that IL-17 transgenic mice have 
induced expression of many chemokines and MMP-9 (38). In 
animal model of cigarette smoke-induced emphysema, chron-
ic smoke exposed mice have significantly higher number of 
IL-17 and IFN-γ producing cells in BAL (39). In contrast, the 
level of IL-17 in sputum is not different between patients with 
COPD  and  control  subjects  (40).
    Th17 cells also produce IL-22, which has been linked to 
chronic inflammatory disease such as rheumatoid arthritis and 
psoriasis (41,42), and has an important role in host defense 
against  extracellular  bacterial  infection  in  the  lung  (43).   
Recent study has shown that number of IL-22 positive cells 
is  increased  in  bronchial  epithelial  cells  of  patients  with 
COPD (44). Another study has demonstrated that IL-22 can 
promote  airway  inflammation  by  acting  in  synergy  with 
IL-17A (45). In this study, bleomycin-induced lung disease is Role of Th17 Cell and Autoimmunity in Chronic Obstructive Pulmonary Disease
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ameliorated in IL-22 deficient mice or IL-22 blocking antibody 
treated mice, and pathological role of IL-22 is seen only in 
the presence of IL-17A. Interestingly, IL-23 that appears to be 
essential to expand and maintain Th17 cells plays a pivotal 
role  in  the  establishment  and  maintenance  of  inflammatory 
autoimmune diseases. In particular, mice genetically deficient 
i n  I L - 2 3  a r e  h i g h l y  r e s i s t a n t  t o  t h e  d e v e l o p m e n t  o f  a u t o -
immune disease such as multiple sclerosis and rheumatoid ar-
thritis, whereas loss of IL-12 is not (46,47). These studies sug-
gest that IL-23 rather than IL-12 is essential for induction of 
autoimmunity (48). The role of IL-23 in COPD has not been 
well investigated although there is a report in which describes 
increased expression of IL-23 in the lung tissues of patients 
with COPD (44). The exact role of Th17 immune responses 
in the development of COPD is still not well studied. As it 
may  provide  a  potentially  important  therapeutic  target  for 
COPD, the additional careful studies are needed to investigate 
the  precise  role  of  Th17  responses  in  COPD.
AUTOIMMUNITY IN COPD
As discussed earlier, there are possible roles of chronic in-
flammation  and  Th17-mediated  immune  responses  in  the 
pathogenesis  of  COPD.  However,  not  all  chronic  inflam-
mation  and/or  Th17-mediated  immune  pathology  are  asso-
ciated with autoimmune diseases. It has been recently pro-
posed that COPD could be an autoimmune disease triggered 
by tobacco smoke (49,50). A potential role for adaptive im-
mune response in COPD has been suggested that expansion 
of  lung  CD4  or  CD8  T  cells  with  oligoclonality  in  patients 
with  COPD  or  murine  emphysema  model  (10,12).    These 
studies have demonstrated that chronic cigarette smoke ex-
posure in mice cause oligoclonal expansions of CD8 T cells 
from lungs, and this response persist despite smoking cessa-
tion (10). The analysis of T cell receptor (TcR) repertoire re-
vealed the oligoclonality of CD4 T cells from lungs of COPD 
patients. These studies suggested that there is a recruitment 
of antigen-specific T cells to the lung and cell-mediated im-
munity may play a critical role in the pathogenesis of COPD 
(12). In addition, it have been reported that T cells generated 
by cigarette smoke exposure are pathogenic in the develop-
ment  of  emphysema  phenotype  in  mice  (11).  Importantly, 
this report demonstrated that adoptive transfer of pathogenic 
T cells into the recombination activating gene-2 (Rag-2) defi-
cient mice could induce the emphysema phenotype regard-
less  of  subsequent  smoking  exposure  on  recipient  mice.  It 
indicates  that  T  cells  by  themselves  generated  by  cigarette 
smoke  exposure  could  be  pathogenic  and  auto-reactive.   
However, auto-antigens responsible for the development of 
autoimmune  response  are  not  defined  in  this  study.
    Recently, we have shown that peripheral blood CD4 T cells 
from patients with COPD have higher level of IFN-γ but not   
IL-13 in response to elastin peptides, major constituents of the 
e x t r a c e l l u l a r  m a t r i x  i n  l u n g  ( 1 3 ) .  I n  t h i s  s t u d y ,  i t  h a s  a l s o  
been reported that humoral response against elastin peptides 
which was assessed by the presence of anti-elastin antibody 
is markedly increased in subjects with emphysema. Further 
study showed that Th17 cells are present in lung parenchyma 
of patients with emphysema and elastin peptides stimulation 
could differentiate both Th1 and Th17 cells (51). In addition, 
this study demonstrated that lung myeloid DCs were sufficient 
to induce Th1 and Th17 responses of CD4 T cells in lungs 
from  emphysema  patients.  IL-17A,  enhances  secretion  of 
C C L 2 0 ,  a  c h e m o a t t r a c t a n t  f o r  D C s ,  a n d  M M P - 1 2  f r o m  l u n g  
macrophages.  Therefore,  these  studies  suggested  that  lung 
myeloid  DCs  are  responsible  for  induction  of  adaptive  im-
mune response, and elastin protein could act as auto-antigen 
during the pathogenesis of COPD via induction of Th1 and 
Th17 immune responses. It proposes a new molecular mech-
anism focused on autoimmunity in the development of COPD 
and  may  provide  a  therapeutic  target  in  this  disease. 
However, other studies could not detect the evidence of an-
ti-elastin  humoral  immune  response  in  the  COPD  patients 
(52,53). In these reports, titers of auto-antibodies against elas-
tin peptides from sera of patients with COPD were not in-
creased  compared  with  those  of  control  subjects.  At  this 
point, reasons of the discrepancy between studies are unclear 
but  there  are  some  differences.  For  example,  demographic 
profiles of the study population are different and functional 
s i g n i f i c a n c e  o f  a n t i - e l a s t i n  h u m o r a l  r e s p o n s e s  i s  n o t  c o n -
firmed. Identification of auto-antigen(s) that induce the adap-
tive immune response in autoimmune disease can provide an 
important  clue  in  understanding  the  pathogenesis  of  the 
disease.  Therefore,  a  great  deal  of  additional  work  will  be 
required to identify the auto-antigen(s) and elucidate the ex-
act  functional  role  of  autoimmune  response  in  the  patho-
genesis  of  COPD.
CONCLUSIONS
Whereas tobacco smoking is a well-known risk factor for the 
development of COPD, the molecular basis for individual sus-Role of Th17 Cell and Autoimmunity in Chronic Obstructive Pulmonary Disease
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ceptibility and disease progression remains largely unknown.   
Several mechanisms including chronic inflammation, cellular 
senescence, and apoptosis are proposed in the contribution 
of the disease development and progression. In addition, a 
number  of  different  studies  have  suggested  roles  of  Th17 
cell-mediated  immune  response  and  autoimmunity  in  the 
pathogenesis of COPD. Further, recent studies have suggested 
that elastin, a major constituent of the extracellular matrix in 
the lungs,  can act as  auto-antigen  in the disease.  Although 
COPD is one of the major concerns in global public health, 
until now there is no effective treatment that can alleviate the 
disease progression or severity. Better immunological under-
standing  is  needed  to  determine  the  exact  role  of  auto-
immunity  in  COPD,  as  it  might  provide  a  new  opportunity 
to  control  the  disease.
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